SiDMAP: A metabolomics approach to assess the effects of drug candidates on the dynamic properties of biochemical pathways

Expert Opinion on Drug Discovery

Volumn 1, Issue 4, 2006, Pages 369-377

  Maguire, Greg ^a   Lee, Paul ^a   Manheim, David ^a   Boros, Laszlo ^a  

^a SiDMAP   (United States)

Author keywords

biochemical pathway; cancer; diabetes; metabolic syndrome; metabolite; metabolomics; tyrosine kinase inhibitor

Indexed keywords

EID: 34249079641     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.1.4.369     Document Type: Review

References (27)

1. DI MASI, JA, HANSEN RW, GRABOWSKI HG: The price of innovation: New estimates of drug development costs. J. Health Econ. (2003) 22:151-185. (Pubitemid 36279392)
2. DUYK G: Attrition and translation. Science (2003) 302 (5645):603-605. (Pubitemid 37310908)
3. TURNER SM, HELLERSTEIN MK: Emerging applications of kinetic biomarkers in preclinical and clinical drug development. Curr. Opin. Drug Disc. Dev. (2005) 8:115-126. (Pubitemid 40116337)
4. ZAMBONI N, SAUER U: Model-independent fluxome profiling from 2H and 13C experiments for metabolic variant discrimination. Genome Biol. (2004) 5:R99.
5. HELLERSTEN MK, MURPHY E: Stable isotope-mass spectrometric measurements of molecular fluxes in vivo: emerging applications in drug development. Curr. Opin. Mol. Ther. (2004) 6:249-264. (Pubitemid 38997126)
6. HARRIGAN GG: Meabolomics a systems contribution to pharmaceutical discovery and drug development. Drug Discov. World (2006) Spring:39-46.
7. LEE WN: Mass isotopomer study of the non-oxidative pathways of the pentose cycle with [1,2-13C2] glucose. Am. J. Physiol. (1998) 274:E843-E851.
8. FLEGAL KM, CARROLL MD, OGDEN CL, JOHNSON CL: Prevalence and trends in obesity among US adults, 1999-2000. JAMA (2002) 288:17230-1727.
9. ECKEL RH, GRUNDY SM, ZIMMET PZ: The metabolic syndrome. Lancet (2005) 365:1415-1428. (Pubitemid 40523737)
10. HE TC, CHAN TA, VOGELSTEIN B, KINZLER KW: PPAR-is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell (1999) 99:335-345. (Pubitemid 29519912)
11. HARMAN FS, NICOL CJ, MARIN HE, WARD JM, GONZALEZ FJ, PETERS JM: Peroxisome proliferator-activated receptorattenuates colon carcinogenesis. Nat. Med. (2004) 10:481-483. (Pubitemid 38667905)
12. LEE WNP, BASSILIAN S, LIM S, BOROS LG: Loss of regulation of lipogenesis in the Zucker diabetic (ZDF) rat. Am. J. Physiol. Endocrinol. Metab. (2000) 279:E425-E432.
13. BASSILIAN S, AHMED S, LIM SK, BOROS LG, MAO CS, LEE WN: Loss of regulation of lipogenesis in the Zucker diabetic rat. II. Changes in stearate and oleate synthesis. Am. J. Physiol. Endocrinol. Metab. (2002) 282:E507-E513. (Pubitemid 34654764)
14. BOROS LG et al.: Metabolic profiling of cell growth and death in cancer ; applications in drug discovery. Drug Discov. Today (2002) 7:364-372. (Pubitemid 34226656)
15. BOREN J et al.: The stable isotope-based dynamic metaolic profile of butyrate-induced HT29 cell differentiation. J. Biol. Chem. (2003) 278:395-402.
16. VIZAN P et al.: K-ras codon-specific mutations produce distinctive metabolic phemotypes in NIH3T3 mice [corrected] fibroblasts. Cancer Res. (2005) 65:5512-5515. (Pubitemid 40911149)
17. SMITH TA: FDG uptake, tumor characteristics and response to therapy: a review. Nucl. Med. Commun. (1998) 19:97-105. (Pubitemid 28189177)
18. EIGENBRODT E et al.: Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Crit. Rev. Oncol. (1992) 3:91-115.
19. LEE WNP: Characterizing phenotype with tracer based metabolomics. Metabolomics (2006) (In Press).
20. BOROS LG, SERKOVA NJ, CASCANTE MS, LEE WNP: Use of metabolic pathway flux information in targeted cancer drug design. Drug Discov. Today: Ther. Strategies (2004) 4:435-443. (Pubitemid 40197589)
21. BOROS LG, BRACKETT DJ, HARRIGAN GG: Metabolic biomarker and kinase drug target discovery in cancer using stable-isotope based dynamic metabolic profiling (SIDMAP). Curr. Cancer Drug Targets (2003) 3:447-455.
22. BOREN J et al.: Gleevec (ST1-571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J. Biol. Chem. (2001) 276:37747-37753.
23. SELIVANOV VA, PUIGJANER J, SILLERO A et al.: An optimized algorithm for flux estimation from isotopomer distribution in glucose metabolites. Bioinformatics (2004) 20:3387-3397. (Pubitemid 40136773)
24. SELIVANOV VA et al.: Rapid stimulation and analysis of isotopomer distributions using constraints based on enzyme mechanisms: an example from HT29 cancer cells. Bioinformatics (2005) 21:3558-3564. (Pubitemid 41236001)
25. ABEL ED, PERONI O, KIM JK et al.: Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature (2001) 409:729-733. (Pubitemid 32144519)
26. SERKOVA NS, BOROS LG: Detection of resistance to imatinib by metabolic profiling. Pharmacodiagnostics (2006) 5:293-302.
27. ROSEN ED, WALKEY CJ, PUIGSERVER P, SPIEGELMAN BM: Transcriptional regulation of adipogenesis. Genes Dev. (2000) 11:1293-1307. (Pubitemid 30397073)